Form 144 Avidity Biosciences, Filed by: Boyce Sarah
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities
June 13, 2024 5:17 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Avidity Biosciences (NASDAQ: RNA) to $45.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This morning, Avidity reported compelling biomarker (>50% reduction in DUX4 related gene panels) and functional strength improvement data in FSHD (a rare muscle disorder) patients treated with... More
